Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.

Jonathan C. Oh,M. Barve,Carolyn M. Matthews,E. Colin Koon,T. Heffernan,B. Fine,E. Grosen,Melanie K. Bergman,Evelyn L Fleming,L. Demars,L. West,D. Spitz,H. Goodman,K. Hancock,G. Wallraven
DOI: https://doi.org/10.1016/j.ygyno.2016.09.018
IF: 5.304
2016-12-01
Gynecologic Oncology
Abstract:
What problem does this paper attempt to address?